Near-complete response to low-dose ceritinib in recurrent infantile inflammatory myofibroblastic tumour

Mostrar otras versiones (1)

BACKGROUND: Infantile inflammatory myofibroblastic tumour (IMT) is rare and the majority are driven by anaplastic lymphoma kinase (ALK) rearrangements. Previous literature on the use of ALK inhibitors in paediatric IMTs is extremely limited with no published literature on the use in infants. Crizoti...

Descripción completa

Detalles Bibliográficos
Autores principales: Mittal, Abhenil, Gupta, Aarushi, Rastogi, Sameer, Barwad, Adarsh, Sharma, Swati
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057779/
https://www.ncbi.nlm.nih.gov/pubmed/33912240
http://dx.doi.org/10.3332/ecancer.2021.1215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057779/
https://www.ncbi.nlm.nih.gov/pubmed/33912240
http://dx.doi.org/10.3332/ecancer.2021.1215

Ejemplares similares